Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating mirikizumab for moderately to severely active ulcerative colitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 3 | Status: RECRUITING